Capital Asset Advisory Services LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,118 shares of the company’s stock, valued at approximately $117,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Black Swift Group LLC purchased a new position in Moderna during the fourth quarter worth about $26,000. Catalyst Capital Advisors LLC purchased a new position in Moderna during the fourth quarter worth about $29,000. Clearview Wealth Advisors LLC purchased a new position in Moderna during the fourth quarter worth about $32,000. Jeppson Wealth Management LLC purchased a new position in Moderna during the third quarter worth about $33,000. Finally, Lindbrook Capital LLC grew its position in Moderna by 81.1% during the fourth quarter. Lindbrook Capital LLC now owns 335 shares of the company’s stock worth $35,000 after buying an additional 150 shares in the last quarter. Institutional investors own 51.21% of the company’s stock.
MRNA stock opened at $131.47 on Thursday. Moderna, Inc. has a fifty-two week low of $31.32 and a fifty-two week high of $189.26. The business’s 50 day moving average price is $142.99 and its two-hundred day moving average price is $120.18. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.43 and a current ratio of 2.43. The company has a market capitalization of $52.66 billion, a price-to-earnings ratio of -81.15, a price-to-earnings-growth ratio of 0.53 and a beta of 1.73.
MRNA has been the subject of several research analyst reports. Oppenheimer lifted their price target on Moderna from $178.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, February 1st. Brookline Capital Management lifted their price target on Moderna from $180.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, March 4th. Needham & Company LLC lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $139.00 price target on shares of Moderna in a research note on Friday, December 11th. Finally, Wells Fargo & Company lifted their price target on Moderna from $129.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, February 1st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. Moderna currently has a consensus rating of “Hold” and a consensus price target of $150.56.
In related news, Director Noubar Afeyan sold 1,836,766 shares of the company’s stock in a transaction that occurred on Monday, February 22nd. The stock was sold at an average price of $164.22, for a total value of $301,633,712.52. Following the sale, the director now owns 2,101,703 shares in the company, valued at approximately $345,141,666.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 12th. The stock was sold at an average price of $185.00, for a total value of $925,000.00. Following the completion of the sale, the president now owns 1,624,597 shares in the company, valued at approximately $300,550,445. The disclosure for this sale can be found here. Insiders have sold a total of 5,667,766 shares of company stock worth $824,359,096 in the last quarter. Company insiders own 29.20% of the company’s stock.
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
Featured Story: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.